Baclofen Sorbitol Naltrexone Composition for Neuropathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Charcot-Marie-Tooth disease and traumatic neuropathies lack effective solutions for promoting nerve regeneration and myelination, particularly in cases involving genetic and mechanical neuronal insults.
Innovation Solution
A composition comprising baclofen, sorbitol, and a compound such as naltrexone, pilocarpine, or mifepristone, administered simultaneously, separately, or sequentially, to promote nerve regeneration and myelination in subjects with traumatic neuropathies or mechanical neuronal insults.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for Charcot-Marie-Tooth disease and traumatic neuropathies, then existing therapeutic options are maintained, but effective nerve regeneration and myelination are not achieved
Solution Approach 1:
The patent combines multiple compounds (baclofen, sorbitol, and one or more additional compounds such as pilocarpine, methimazole, mifepristone, naltrexone, rapamycin, flurbiprofen, or ketoprofen) into a single therapeutic composition. This combination approach merges the effects of individual drugs to achieve synergistic nerve regeneration and myelination, addressing the insufficiency of current single-agent treatments for Charcot-Marie-Tooth disease and traumatic neuropathies.
2Ease of operation
If single compound treatments are used, then treatment simplicity is maintained, but nerve regeneration and myelination efficacy are insufficient
Solution Approach 1:
The invention merges multiple active compounds into a single multi-component composition that can be administered together, maintaining relative treatment simplicity while achieving enhanced therapeutic effectiveness through synergistic interactions between the compounds for promoting nerve regeneration and myelination.
Solution Approach 2:
The patent creates a composite therapeutic composition comprising baclofen, sorbitol, and additional compounds selected from a specific group. This composite formulation integrates multiple pharmacological agents with different mechanisms of action to simultaneously target multiple pathways involved in nerve regeneration and myelination, thereby improving therapeutic effectiveness while maintaining ease of administration.
3Stability of the object's composition
If no specific therapeutic intervention is applied, then existing nerve damage state is maintained, but PMP22 expression remains abnormal and myelination is disrupted
Solution Approach 1:
The patent employs compounds that specifically modulate PMP22 gene expression and protein levels. Baclofen, sorbitol, and the additional compounds work to normalize aberrant PMP22 expression parameters, thereby restoring proper myelination and nerve integrity in Charcot-Marie-Tooth disease models without causing harmful overexpression or complete suppression.
Data Source
Figure 1A~1D
Figure 2A~2D
Figure 3A~3B
AI summary
The present invention relates to compositions and methods for the treatment of the mechanical neuronal insu